Sunday, September 6, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Commodities

Ferrexpo’s London Listing Resumes as $100 Million Rescue Priced at Steep Discount

Rodolfo Hanigan by Rodolfo Hanigan
September 6, 2026
in Commodities, European Markets
0
Ferrexpo Stock
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

The suspension that has kept Ferrexpo’s shares off the London market since early May is finally lifting, with trading set to resume at 7:30 a.m. on Monday. The restart follows the miner’s publication of its 2025 annual report on Wednesday and comes just days before the newly issued shares from its $100 million capital raise are admitted to trading on September 22.

The fundraising, completed at 16.5 pence per share, carries a 42.3 percent discount to the 28.6 pence closing price recorded on April 30 — the last session before the shares were frozen. The placement involved 269,309,091 new ordinary shares through a private placement and a further 179,539,393 shares via subscription, together representing roughly 73.1 percent of the company’s previous share capital. That dilution helps explain the depth of the discount investors demanded.

Two Ukrainian businessmen with long-standing ties to the iron ore producer are shouldering the bulk of the raise. Andrij Verevskyi, the owner of agricultural group Kernel, is taking roughly half the emission — about $50 million — in exchange for 224.4 million new shares. Fevamotinico, the investment vehicle of Ferrexpo founder Kostyantyn Zhevago, is subscribing for another 40 percent of the volume. The shareholder meeting formally approving the capital increase is scheduled for September 21, with the new shares due to begin trading the following day.

A balance sheet under siege

The urgency behind the fundraising becomes clear in the full-year figures. Revenue fell 16 percent to $787 million, dragged down by weaker realised prices and a shift toward lower-grade iron ore concentrate. EBITDA more than halved to $28 million, while the company swung to a net loss of $223.9 million — a sharp deterioration from the $50 million loss recorded the prior year. A non-cash impairment charge of $154 million on operating assets accounted for much of the damage.

Should investors sell immediately? Or is it worth buying Ferrexpo?

Production tells a similarly stark story. Pellet output dropped 47 percent to 3.22 million tonnes, though total production across all products fell a comparatively milder 9 percent to 6.1 million tonnes. The operational disruptions stem from war-related damage and logistics bottlenecks that have periodically forced the company’s Ukrainian processing plants to stand idle, most recently following an incident in the Black Sea more than a month ago.

Cash reserves are thinning fast. The company held $58 million at year-end, down from $106 million at the start of the period, with the position exacerbated by Ukrainian authorities withholding value-added tax refunds. The tax administration has cited the personal sanctions imposed on Zhevago as grounds for the holdback, leaving Ferrexpo with a net VAT receivable in Ukraine exceeding $88 million as of June 30 — including $61 million withheld during the reporting period.

No guidance, mounting uncertainty

Management has declined to issue production or cost guidance for 2026, citing the impossibility of reliable forecasting amid the political and logistical volatility in Ukraine. That caution extends to the company’s relationship with the tax authorities, whose stance on VAT refunds remains a live issue for liquidity.

The annual report is expected to reach shareholders around September 10, accompanied by a circular convening an extraordinary general meeting. For existing investors, Monday’s reopening of the market offers the first real test of sentiment: how the market weighs the combination of severe dilution, persistent cash constraints and an operating environment that remains hostage to forces beyond the company’s control. The participation of Verevskyi and Fevamotinico suggests core shareholders at least see a path to restarting mining operations — even if the price of that conviction is a deeply discounted entry for those willing to back the recovery.

Ad

Ferrexpo Stock: Buy or Sell?! New Ferrexpo Analysis from September 6 delivers the answer:

The latest Ferrexpo figures speak for themselves: Urgent action needed for Ferrexpo investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.

Ferrexpo: Buy or sell? Read more here...

Tags: Ferrexpo
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Gold Stock
Commodities

Gold’s Diverging Demand Signals Leave Bullion’s Rally on Shaky but Supportive Ground

September 6, 2026
Vulcan Energy Stock
Analysis

Vulcan Energy’s Ludwig Math Is Compelling — The Market Needs More Than Numbers

September 6, 2026
Almonty Stock
Analysis

Almonty’s Sangdong Transition: The Gap Between Analyst Targets and Ore That Actually Moves

September 6, 2026
Next Post
Outlook Therapeutics Stock

Outlook Therapeutics Puts Reimbursement Paperwork at the Center of Its LYTENAVA Commercial Push

Recommended

Kraft Heinz Stock

Kraft Heinz Shares Face Analyst Pessimism Amid Growth Concerns

10 months ago
OraSure Stock

OraSure Faces Hostile Takeover Threat as Investor Tensions Mount

1 year ago
Tesla Stock

Tesla’s China Performance and Strategic Shifts Present a Complex Picture

6 months ago
Rex American Stock

Rex American Resources Announces Stock Split Amid Mixed Quarterly Results

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Bayer’s September Crossroads: A Courtroom Verdict and a Crop Science Rebound Converge

Redcare Pharmacy’s Next CEO Brings Marketplace Pedigree — But the Share Price Is Still Searching for a Floor

Deutz’s Two-Front Advance: An Indian Engine Pact Arrives as the FFG Takeover Nears Completion

Take-Two’s Blockbuster Buzz Meets a Stock That Refuses to Play Along

Amphenol’s Post-Split Reality Check: The Order Book, Not the Mechanics, Is the Story

TKMS: Record Order Book and a Finished Submarine Chapter, Yet the Share Price Keeps Drifting Lower

Trending

Outlook Therapeutics Stock
Analysis

Outlook Therapeutics Puts Reimbursement Paperwork at the Center of Its LYTENAVA Commercial Push

by Kennethcix
September 6, 2026
0

The administrative machinery of US healthcare reimbursement rarely moves markets — but for Outlook Therapeutics, a single...

Ferrexpo Stock

Ferrexpo’s London Listing Resumes as $100 Million Rescue Priced at Steep Discount

September 6, 2026
Rocket Lab Stock

Rocket Lab’s Valuation Gap Widens as Iridium Deal Clears Its Final Hurdle

September 6, 2026
Bayer Stock

Bayer’s September Crossroads: A Courtroom Verdict and a Crop Science Rebound Converge

September 6, 2026
Redcare Pharmacy Stock

Redcare Pharmacy’s Next CEO Brings Marketplace Pedigree — But the Share Price Is Still Searching for a Floor

September 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Outlook Therapeutics Puts Reimbursement Paperwork at the Center of Its LYTENAVA Commercial Push
  • Ferrexpo’s London Listing Resumes as $100 Million Rescue Priced at Steep Discount
  • Rocket Lab’s Valuation Gap Widens as Iridium Deal Clears Its Final Hurdle

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com